Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 3 1

Status

Active not recruiting 9Completed 7Terminated 6Recruiting 4Withdrawn 2Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Sarcoma 2Gynecologic 2Genitourinary 2Plasma cell 1Myeloid 1Lymphoid 1Head & Neck 1Gastrointestinal 1Breast 1

Conditions

Stroke 1Sarcoma 1Pulmonary Disease, Chronic Obstructive 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Kidney Failure, Chronic 1Diabetes Mellitus 1Coronary Artery Disease 1COVID-19 1Breast Neoplasms 1

Interventions

pembrolizumab 19Docetaxel 16Magnetic Resonance Spectroscopy 14Prednisone 13Radiotherapy 11bicalutamide 10Leuprolide 10Abiraterone Acetate 9Radiosurgery 8Cyclophosphamide 8Biopsy 8avelumab 7atezolizumab 6Specimen Handling 6Interleukin-2 6Gemcitabine 6Bevacizumab 6Androgen Antagonists 6tremelimumab 5gallium 68 PSMA-11 5apalutamide 5acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 5Surveys and Questionnaires 5Sunitinib 5Paclitaxel 5Metformin 5Injections 5Goserelin 5Cisplatin 5ALT-803 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Disulfides × Genitourinary × Clear all
NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

OHSU Knight Cancer Institute

Phase EARLY_PHASE1 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT04361552 2020-06-18

Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)

Emory University

Phase 3 Withdrawn
Genitourinary

COVID-19, Coronary Artery Disease, Diabetes Mellitus, Kidney Failure, Chronic, Neoplasms, Stroke, Pulmonary Disease, Chronic Obstructive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡